(Press-News.org) BOSTON--A hormone-depleting drug approved last year for the treatment of metastatic prostate cancer can help eliminate or nearly eliminate tumors in many patients with aggressive cancers that have yet to spread beyond the prostate, according to a clinical study to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO), June 1-5, in Chicago.
The phase II clinical trial, led by investigators at Dana-Farber Cancer Institute and other research centers, examined the use of the drug abiraterone acetate (Zytiga(R)) in combination with prednisone and surgery in 58 men with high-risk prostate cancer isolated to the prostate gland. Participants received either three or six months of the two-drug regimen followed by surgery to remove the prostate. When the treatment was complete, pathology exams showed that one-third of the participants had no or almost no tumor tissue left.
"Very high-risk cancers localized to the prostate are rarely cured by prostatectomy alone," says the study's lead author, Mary-Ellen Taplin, MD, of Dana-Farber. "Therapies that combine surgery with older androgen-inhibiting drugs have not historically improved outcomes. This unmet need has given rise to efforts to develop new drugs capable of more completely reducing androgen levels within the prostate tumors."
Taplin will present the data (abstract 4521) on Saturday, June 2, at 8 a.m. CT, Arie Crown Theater, McCormick Place.
Androgen, the male hormone, provides the fuel for prostate cancer growth. Conventional therapies target androgen production in the testes and adrenal glands, but not within the tumor itself. Abiraterone acetate is capable of blocking androgen production in all three sites.
In the study, researchers used half the dose of prednisone (a steroid) standardly given with abiraterone acetate. This lower dose, it is hoped, would reduce the side effects associated with steroids while maintaining its benefits of protecting particular steroid imbalances associated with abiraterone. Since there were no increased side effects from abiraterone, the researchers feel that the lower dose of prednisone (5mg daily) is adequate for most patients.
"Most of the patients in this study had large tumors, high grade prostate cancers and were at high risk for cancer spread," Taplin remarks. "We're very encouraged by the results and have begun another phase II study investigating another novel androgen signaling inhibitor, MDV3100, in the neoadjuvant setting for high risk prostate cancer. We are also developing a clinical trial program investigating the addition of the investigational drug ARN509 to abiraterone. To prove the overall benefit of intensive androgen deprivation treatment in conjunction with prostatectomy, a large randomized clinical trial will need to be done."
INFORMATION:
The research was funded in part by Jansen Research & Development and The Prostate Cancer Foundation (PCF). The clinical trial was performed through the Prostate Cancer Clinical Trial Consortium, which is funded by the Department of Defense and PCF.
In addition to Taplin, the study's other authors included researchers from Dana-Farber; Fred Hutchinson Cancer Research Center; University of Washington School of Medicine; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital; M.D. Anderson Cancer Center; and Janssen Research & Development.
Dana-Farber Cancer Institute (www.dana-farber.org) is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute. It provides adult cancer care with Brigham and Women's Hospital as Dana-Farber/Brigham and Women's Cancer Center and it provides pediatric care with Children's Hospital Boston as Dana-Farber/Children's Hospital Cancer Center. Dana-Farber is the top ranked cancer center in New England, according to U.S. News & World Report, and one of the largest recipients among independent hospitals of National Cancer Institute and National Institutes of Health grant funding. Follow Dana-Farber on Twitter: @danafarber or Facebook: facebook.com/danafarbercancerinstitute.
Hormone-depleting drug shows promise against localized high-risk prostate tumors
2012-05-17
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
The New York and New Jersey Partnership Dispute Guide
2012-05-17
New York and New Jersey Partnership Lawyer Charles N. Internicola has announced the release of "The New York and New Jersey Partnership Dispute Guide: A Practical no nonsense guide to educate, inform and empower partners, shareholders and members faced with a serious partnership dispute." This book is for you if you have partners who now jeopardize and threaten your business and livelihood.
Having seen the devastating and unnecessary effect that a "partnership dispute" may have on a thriving business, Mr. Internicola wrote the book:
"...to ...
New advice on medication disposal: Trash beats take-back, new study suggests
2012-05-17
ANN ARBOR, Mich.—Returning extra medicine to the pharmacy for disposal might not be worth the extra time, money or greenhouse gas emissions, according to a University of Michigan study that is the first to look at the net effects of so-called take-back programs.
The new evidence suggests that discarding unused drugs in the trash is a better option to limit the risk of poisoning and at the same time curb pollution of both water and air.
To arrive at this conclusion, the researchers compared the total emissions created by take-back, trash and toilet disposal methods. ...
First Capital Payments Eyes Far-Reaching Opportunity with New App Offering Consumers New, Neat Way to Pay
2012-05-17
All across the country, consumers and merchants are engaging in a new form of commerce: Google Wallet. Google Wallet is the most notable name of an emerging number of technologies relying on near field communication to allow consumers to pay for goods and services with a simple wave of their smartphone. Consumers love the convenience and novelty of these technologies while merchants love the lower cost and ability to create digital gift and reward cards to attract new customers. There will come a time when we each carry one device to unlock doors, pay for goods, contact ...
Girl child marriages decline in south Asia, but only among youngest
2012-05-17
Each year, more than 10 million girls under the age of 18 marry, usually under force of local tradition and social custom. Almost half of these compulsory marriages occur in South Asia. A new study suggests that more than two decades of effort to eliminate the practice has produced mixed results.
Writing in the May 16, 2012 issue of Journal of the American Medical Association, Anita Raj, PhD, professor of medicine in the University of California, San Diego School of Medicine, and colleagues, report that marriage rates for girls under the age of 14 in India, Nepal, Pakistan ...
Danuser HAMMER - 800-733-0275 Hamilton Equipment - The NEW Danuser HAMMER VIDEO
2012-05-17
Hamilton Equipment -800-733-0275 - is proud to introduce the new Danuser HAMMER post driver, in addition to the full line of stocking Danuser wholegoods and parts. This one-person HAMMER post driver has an innovative design to achieve a full stroke with every cycle - maximizing the impact force. The HAMMER does NOT use springs, hydraulic cylinders or a return line.
Watch our Hammer video to see it crush the competition! A must-see!
The Danuser HAMMER has a free fall weight design that keeps the hammer weight from striking the top of the posts. And the grapple option ...
Early substance use linked to lower educational achievement
2012-05-17
AUDIO:
Using alcohol, nicotine or illegal drugs at a young age decreases the likelihood that a person will finish college. Studying twins, Washington University researchers have found that those who began...
Click here for more information.
Researchers have found evidence that early drug and alcohol use is associated with lower levels of educational attainment.
Studying male twins who served in the military during the Vietnam era, they found that those who began drinking or ...
Smartphones a big help to visually impaired
2012-05-17
MAYWOOD, Ill. -- iPhones and other smartphones can be a huge help to the visually impaired, but few vision doctors are recommending them to patients, according to a study co-authored by a Loyola University Chicago Stritch School of Medicine ophthalmologist.
Researchers surveyed 46 low-vision adults from the Chicago Lighthouse and the Spectrios Institute for Low Vision in Wheaton, Ill. Participants' best-corrected vision ranged from 20/70 to complete blindness.
Researchers found that only 15 percent of patients reported that a vision doctor had recommended smartphones ...
The Childhood Obesity Crisis - One Company Offers a Simple Solution to a Staggering Health Problem
2012-05-17
On May 14, The Weight Of The Nation, a four-part HBO documentary on the subject of childhood obesity was aired. The project is a joint effort by HBO, The Center For Disease Control and Prevention, The Institute Of Medicine and the National Institute of Health. The series will raise the consciousness of the public regarding the staggering facts surrounding childhood obesity. While creating awareness is laudable, one company believes solutions are urgently needed and has recently developed a product that can provide that solution. The new product is both effective and affordable. ...
Heliconius butterfly genome explains wing pattern diversity
2012-05-17
Pooling funds and putting their heads together, more than 70 scientists from 9 institutions including the Smithsonian Tropical Research Institute, sequenced the entire genome of the butterfly genus Heliconius, a brightly colored favorite of collectors and scientists since the Victorian era. Their results are published in the prestigious journal, Nature.
The genome of the Postman butterfly, Panama's Heliconius melpomene, helps scientists understand how the stunning diversity of wing color patterns in tropical butterflies evolved. Heliconius species are highly distasteful. ...
Children with cancer have complete responses in a Children's Oncology Group phase 1 trial
2012-05-17
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children's Oncology Group (COG). The results were "an exciting proof-of-principle" for the targeted treatment, said the study leader, Yaël P. Mossé, M.D., a pediatric ...